Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05426434
Other study ID # 2021-4107
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date August 31, 2022
Est. completion date December 2025

Study information

Verified date October 2023
Source Menzies School of Health Research
Contact Holger Unger, PhD MBChB
Phone +61889468411
Email holger.unger@menzies.edu.au
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) plus dihydroartemisinin-piperaquine (DP) significantly reduces the risk of malaria infection (primary outcome) and adverse birth outcomes (key secondary outcome) in an endemic area of Papua New Guinea (PNG), compared to IPTp with SP alone (the current standard of care). To test this hypothesis a double-blinded, placebo-controlled, phase-III, superiority trial will individually randomize 1,172 HIV-uninfected pregnant women enrolled from 12-26 gestational weeks in equal proportions to one of two IPTp arms: 1) SP given every for weeks, or 2) SP+DP given every 4 weeks. DP placebos will be used to ensure adequate blinding is achieved in the study and follow-up will end 28 days after giving birth.


Description:

Plasmodium falciparum and P. vivax infections cause malaria, maternal anemia and interfere with the development of the fetus, thereby increasing the risks of adverse pregnancy outcomes such as miscarriage, stillbirth, premature birth, fetal growth restriction, low birth weight, and infant death. Infected pregnant women are frequently asymptomatic, and current point-of-care tests miss placental and low-density infections. Monthly intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is designed to clear asymptomatic infections and provide post-treatment prophylaxis. The World Health Organization recommends IPTp with SP and long-lasting insecticidal bed nets for the prevention of malaria in pregnancy in endemic areas of sub-Saharan Africa. However, the emergence and spread of high-grade parasite resistance to SP threatens to compromise this strategy. Dihydroartemisinin-piperaquine (DP) is a safe fixed-dose artemisinin-based combination therapy used for the management of uncomplicated P. falciparum and P. vivax malaria in pregnancy and has emerged as a potential candidate to replace SP for IPTp. In comparative trials conducted in high-transmission settings in sub-Saharan Africa IPTp with DP was safe and significantly reduced the risk of P. falciparum infection compared to IPTp with SP. IPTp with DP also reduced the risk of P. vivax parasitemia in Papua Indonesia when compared to a single screen and treat approach. However, DP's superior antimalarial efficacy in African studies did not translate to large reductions in adverse pregnancy outcomes in these trials. This suggests that SP, whilst failing as an antimalarial, may prevent adverse pregnancy events via potent non-malarial effects that are not inherent to DP. For example, SP may provide protection from pathogens other than malaria parasites that are directly or indirectly involved in the causation of adverse pregnancy outcomes. Papua New Guinea (PNG) is characterized by moderate intensity co-transmission of P. falciparum and P. vivax and a high burden of adverse pregnancy outcomes. PNG is the only country outside of Africa that has a policy of IPTp with SP. However, P. vivax resistance to SP is now common, high-grade P. falciparum resistance to SP may be emerging, and DP could provide enhanced antimalarial protection. However, given the high burden of adverse pregnancy outcomes from malaria- and non-malaria related causes, simply replacing SP with DP for IPTp in PNG may not lead to a reduction in adverse birth outcomes. Instead, combining DP with SP for IPTp has the potential to substantially improve health outcomes by reducing the risk of malaria infection whilst harnessing the non-malaria-related benefits of SP. A double-blinded randomized controlled clinical trial will (1) compare the risk of malaria infection among pregnant women randomized to receive monthly IPTp with SP vs. SP+DP; (2) compare the risk of adverse pregnancy outcomes among pregnant women randomized to receive monthly IPTp with SP vs. SP+DP; and (3) compare safety and tolerability of monthly IPTp with SP vs SP+DP. The findings of this trial may have important policy implications, and the evidence generated will inform practice for PNG and sub-Saharan Africa.


Recruitment information / eligibility

Status Recruiting
Enrollment 1172
Est. completion date December 2025
Est. primary completion date February 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 16 Years and older
Eligibility Inclusion Criteria: - Pregnant women between 12-26 weeks' gestation - 16 years of age or older - Viable singleton intrauterine pregnancy - Permanent resident of the study area - Willing to adhere to scheduled and unscheduled study visit procedures - Willing to birth in a study clinic or hospital - Able to provide written informed consent Exclusion Criteria: - Multiple pregnancy (i.e. twins/triplets) - Known heart ailment or other chronic medical condition requiring frequent hospital care - Active medical problem requiring inpatient evaluation at the time of screening - Severe malformations or non-viable pregnancy if observed by ultrasound - Antimalarial therapy in the prior two weeks - Unable to provide written informed consent - Known allergy or contraindication to any of the study drugs - Early or active labour - Known HIV-positive status

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dihydroartemisinin-Piperaquine (DP)
DP (D-Artepp) will be supplied by Fosun Pharma, China. DP will consist of three 40mg/320mg) tablets given once a day for three consecutive days
Sulfadoxine pyrimethamine (SP)
SP (G-COSPE) will be supplied by Fosun Pharma, China. SP will be given as a single dose consisting of three 500mg/25mg tablets.

Locations

Country Name City State
Papua New Guinea Papua New Guinea Institute of Medical Research Madang Madang Province

Sponsors (5)

Lead Sponsor Collaborator
Menzies School of Health Research Curtin University, Liverpool School of Tropical Medicine, Papua New Guinea Institute of Medical Research, University of Melbourne

Country where clinical trial is conducted

Papua New Guinea, 

Outcome

Type Measure Description Time frame Safety issue
Primary Malaria infection in pregnancy 'Malaria infection in pregnancy' is a composite outcome, defined as one or more episode of P. falciparum and/or P. vivax infection, detected by microscopy and/or qPCR in peripheral blood or placental blood, or P. falciparum and/or P. vivax infection, detected as active infection on placental histology. The surveillance period will run from two weeks after the first dose of the first monthly treatment up until and including delivery (numerator) in women who attend at least one scheduled or unscheduled visit during the surveillance period (denominator).
Proportion of women with 'malaria infection in pregnancy'
Starting two weeks after initial dose until and including delivery
Secondary Adverse pregnancy outcome Composite adverse birth outcome is defined as the occurrence of any of the following:
Spontaneous miscarriage: Fetal loss <28 weeks of gestational age
Stillbirth: Infant born deceased at =28 weeks of gestational age
Low birth weight (LBW): Live birth with birth weight <2,500 grams
Preterm birth (PTB): Live birth <37 weeks gestational age
Small-for-gestational age (SGA): Live birth with birth weight-for-gestational-age <10th percentile of the INTERGROWTH-21st reference
Neonatal death: Live birth with neonatal death within the first 28 days of life
Prevalence of adverse pregnancy outcome
Time of delivery up to 28 days postpartum
Secondary Clinical malaria during pregnancy Incidence of new episodes of fever or history of fever plus positive RDT confirmed by microscopy and/or qPCR during pregnancy Starting two weeks after initial dose until and including delivery
Secondary Parasitemia during pregnancy Proportion of samples with parasites detected in maternal peripheral blood samples by microscopy or qPCR Starting two weeks after initial dose until and including delivery
Secondary Composite placental malaria detected by microscopy, qPCR or by histology Prevalence of placental parasites by microscopy, qPCR, or placental histology At time of delivery
Secondary Placental malaria detected by microscopy Prevalence of parasites in placental blood by microscopy At time of delivery
Secondary Placental malaria detected by qPCR Prevalence of parasites in placental blood by qPCR At time of delivery
Secondary Active placental malaria detected by histology Prevalence of active infection (presence of parasites) on histology At time of delivery
Secondary Past placental malaria detected by histology Prevalence of past infection (pigment only) on histology At time of delivery
Secondary Placental malaria detected by histology Prevalence of placental infection (active or past) on histology At time of delivery
Secondary Composite fetal loss and neonatal death Prevalence of fetal loss (spontaneous miscarriage or stillbirth) and neonatal death Time of delivery up to 28 days postpartum
Secondary Composite of SGA-LBW-PTB Prevalence of small for gestational age, low birth weight, and preterm birth At time of delivery
Secondary SGA Prevalence of small for gestational age using the new Intergrowth-21st population reference's 10th centile At time of delivery
Secondary LBW Prevalence of low birth weight At time of delivery
Secondary PTB Prevalence of preterm birth At time of delivery
Secondary Birth weight Mean birthweight At time of delivery
Secondary Neonatal length Neonatal length At time of delivery
Secondary Maternal nutritional status Changes in maternal body mass index (BMI) 8 months from randomisation
Secondary Maternal nutritional status Changes in maternal mid-upper arm circumference (MUAC) 6 months from randomisation
Secondary Maternal anemia during pregnancy and at delivery Proportion of routine haemoglobin measurements <100 g/L 6 months from randomisation
Secondary Maternal hemoglobin levels during pregnancy and at delivery Mean hemoglobin (g/L) at the third trimester antenatal visit and at delivery 6 months from randomisation
Secondary Congenital anemia Prevalence of anaemia (Hb <130 g/L) from newborn cord blood At delivery
Secondary Maternal gametocyte carriage during pregnancy and at delivery Proportion of P. falciparum positive samples with gametocytes at the third trimester antenatal visit and at delivery, by light microscopy and RT-qPCR 6 months from randomisation
Secondary Molecular markers of DP resistance Proportion of parasite positive samples with molecular markers of DP resistance 6 months from randomisation
Secondary Molecular markers of SP drug resistance Proportion of parasite positive samples with molecular markers of SP resistance 6 months from randomisation
Secondary Maternal mortality he death of a woman while pregnant or within 42 days of the end of pregnancy, irrespective of the duration and site of the pregnancy, but not from accidental or incidental causes 8 months from randomisation
Secondary Congenital malformations Any visible external congenital abnormality on surface examination 8 months from randomisation
Secondary Other SAEs and AEs Incidence of AEs and SAEs 8 months from randomisation
Secondary (History) of vomiting study drug Prevalence of vomiting investigational product (IP) twice at the same IP administration visit 6 months from randomisation
Secondary Dizziness Prevalence of dizziness after a course of IP 6 months from randomisation
Secondary Gastrointestinal complaints Prevalence of gastrointestinal complaints after a course of IP 6 months from randomisation
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02315690 - Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland Phase 3